Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Paul Graves Hammerness, M.D.

Title
Institution
Department
Address
Phone
Profile Picture

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Partain PI, White J, Hammerness P. New stimulant formulations for pediatric attention-deficit/hyperactivity disorder: a case-based approach for the primary care provider. Curr Opin Pediatr. 2019 02; 31(1):166-174. PMID: 30531224.
    Citations:    Fields:    
  2. Hauptman AJ, Acar D, Hammerness P, Fogler JM, Stafford D. A Case of Emotional Trauma in the Setting of Neurodevelopmental Disability. Harv Rev Psychiatry. 2018 Nov/Dec; 26(6):384-391. PMID: 30407237.
    Citations:    Fields:    
  3. Biederman J, Hammerness P, Sadeh B, Peremen Z, Amit A, Or-Ly H, Stern Y, Reches A, Geva A, Faraone SV. Diagnostic utility of brain activity flow patterns analysis in attention deficit hyperactivity disorder. Psychol Med. 2017 May; 47(7):1259-1270. PMID: 28065167.
    Citations:    Fields:    Translation:Humans
  4. Hammerness P, Petty C, Faraone SV, Biederman J. Do Stimulants Reduce the Risk for Alcohol and Substance Use in Youth With ADHD? A Secondary Analysis of a Prospective, 24-Month Open-Label Study of Osmotic-Release Methylphenidate. J Atten Disord. 2017 01; 21(1):71-77. PMID: 23264367.
    Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
  5. Chan E, Fogler JM, Hammerness PG. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review. JAMA. 2016 May 10; 315(18):1997-2008. PMID: 27163988.
    Citations: 20     Fields:    Translation:Humans
  6. Sprich SE, Safren SA, Finkelstein D, Remmert JE, Hammerness P. A randomized controlled trial of cognitive behavioral therapy for ADHD in medication-treated adolescents. J Child Psychol Psychiatry. 2016 11; 57(11):1218-1226. PMID: 26990084.
    Citations: 2     Fields:    Translation:Humans
  7. Hammerness PG, Karampahtsis C, Babalola R, Alexander ME. Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks? Expert Opin Drug Saf. 2015 Apr; 14(4):543-51. PMID: 25648243.
    Citations: 2     Fields:    Translation:Humans
  8. Faraone SV, Hammerness PG, Wilens TE. Reliability and Validity of the Before-School Functioning Scale in Children With ADHD. J Atten Disord. 2018 09; 22(11):1040-1048. PMID: 25575616.
    Citations: 3     Fields:    
  9. Munshi K, Alexander ME, Hammerness P. Corrected QT interval changes with atypical antipsychotics. J Am Acad Child Adolesc Psychiatry. 2015 Jan; 54(1):9-10. PMID: 25524785.
    Citations:    Fields:    Translation:Humans
  10. Ulbricht C, Basch E, Cheung L, Goldberg H, Hammerness P, Isaac R, Khalsa KP, Romm A, Rychlik I, Varghese M, Weissner W, Windsor RC, Wortley J. An evidence-based systematic review of elderberry and elderflower (Sambucus nigra) by the Natural Standard Research Collaboration. J Diet Suppl. 2014 Mar; 11(1):80-120. PMID: 24409980.
    Citations:    Fields:    Translation:HumansAnimals
  11. Hammerness P, Fried R, Petty C, Meller B, Biederman J. Assessment of cognitive domains during treatment with OROS methylphenidate in adolescents with ADHD. Child Neuropsychol. 2014; 20(3):319-27. PMID: 23639146.
    Citations: 3     Fields:    Translation:Humans
  12. Biederman J, Pettye CR, Hammerness P, Woodworth KY, Faraon SV. Examining the nature of the association between attention-deficit hyperactivity disorder and nicotine dependence: a familial risk analysis. Can J Psychiatry. 2013 Mar; 58(3):177-83. PMID: 23461889.
    Citations: 1     Fields:    Translation:Humans
  13. Surman CB, Hammerness PG, Pion K, Faraone SV. Do stimulants improve functioning in adults with ADHD? A review of the literature. Eur Neuropsychopharmacol. 2013 Jun; 23(6):528-33. PMID: 23391411.
    Citations: 7     Fields:    Translation:Humans
  14. Ulbricht C, Basch E, Chao W, Conquer J, Costa D, Culwell S, Flanagan K, Guilford J, Hammerness P, Hashmi S, Isaac R, Rusie E, Serrano JM, Ulbricht C, Vora M, Windsor RC, Woloszyn M, Zhou S. An evidence-based systematic review of vitamin A by the natural standard research collaboration. J Diet Suppl. 2012 Dec; 9(4):299-416. PMID: 23157584.
    Citations:    Fields:    Translation:Humans
  15. Hammerness P, Joshi G, Doyle R, Georgiopoulos A, Geller D, Spencer T, Petty CR, Faraone SV, Biederman J. Do stimulants reduce the risk for cigarette smoking in youth with attention-deficit hyperactivity disorder? A prospective, long-term, open-label study of extended-release methylphenidate. J Pediatr. 2013 Jan; 162(1):22-7.e2. PMID: 22878114.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  16. Biederman J, Petty CR, Hammerness P, Batchelder H, Faraone SV. Cigarette smoking as a risk factor for other substance misuse: 10-year study of individuals with and without attention-deficit hyperactivity disorder. Br J Psychiatry. 2012 Sep; 201(3):207-14. PMID: 22844023.
    Citations: 7     Fields:    Translation:Humans
  17. Fried R, Surman C, Hammerness P, Petty C, Faraone S, Hyder L, Westerberg D, Small J, Corkum L, Claudat K, Biederman J. A controlled study of a simulated workplace laboratory for adults with attention deficit hyperactivity disorder. Psychiatry Res. 2012 Dec 30; 200(2-3):949-56. PMID: 22608823.
    Citations:    Fields:    Translation:Humans
  18. Hammerness P, Zusman R, Systrom D, Surman C, Baggish A, Schillinger M, Shelley-Abrahamson R, Wilens TE. A cardiopulmonary study of lisdexamfetamine in adults with attention-deficit/hyperactivity disorder. World J Biol Psychiatry. 2013 May; 14(4):299-306. PMID: 22559155.
    Citations: 8     Fields:    Translation:Humans
  19. Adler LA, Shaw DM, Spencer TJ, Newcorn JH, Hammerness P, Sitt DJ, Minerly C, Davidow JV, Faraone SV. Preliminary examination of the reliability and concurrent validity of the attention-deficit/hyperactivity disorder self-report scale v1.1 symptom checklist to rate symptoms of attention-deficit/hyperactivity disorder in adolescents. J Child Adolesc Psychopharmacol. 2012 Jun; 22(3):238-44. PMID: 22537184.
    Citations: 10     Fields:    Translation:Humans
  20. Biederman J, Fried R, Hammerness P, Surman C, Mehler B, Petty CR, Faraone SV, Miller C, Bourgeois M, Meller B, Godfrey KM, Baer L, Reimer B. The effects of lisdexamfetamine dimesylate on driving behaviors in young adults with ADHD assessed with the Manchester driving behavior questionnaire. J Adolesc Health. 2012 Dec; 51(6):601-7. PMID: 23174471.
    Citations: 4     Fields:    Translation:Humans
  21. Surman CB, Hammerness PG, Petty C, Spencer T, Doyle R, Napolean S, Chu N, Yorks D, Biederman J. A pilot open label prospective study of memantine monotherapy in adults with ADHD. World J Biol Psychiatry. 2013 May; 14(4):291-8. PMID: 22436083.
    Citations: 6     Fields:    Translation:Humans
  22. Biederman J, Fried R, Hammerness P, Surman C, Mehler B, Petty CR, Faraone SV, Miller C, Bourgeois M, Meller B, Godfrey KM, Reimer B. The effects of lisdexamfetamine dimesylate on the driving performance of young adults with ADHD: a randomized, double-blind, placebo-controlled study using a validated driving simulator paradigm. J Psychiatr Res. 2012 Apr; 46(4):484-91. PMID: 22277301.
    Citations: 14     Fields:    Translation:Humans
  23. Wozniak J, Gönenç A, Biederman J, Moore C, Joshi G, Georgiopoulos A, Hammerness P, McKillop H, Lukas SE, Henin A. A magnetic resonance spectroscopy study of the anterior cingulate cortex in youth with emotional dysregulation. Isr J Psychiatry Relat Sci. 2012; 49(1):62-9. PMID: 22652930.
    Citations: 4     Fields:    Translation:Humans
  24. Joshi G, Petty C, Wozniak J, Faraone SV, Doyle R, Georgiopoulos A, Hammerness P, Walls S, Glaeser B, Brethel K, Yorks D, Biederman J. A prospective open-label trial of quetiapine monotherapy in preschool and school age children with bipolar spectrum disorder. J Affect Disord. 2012 Feb; 136(3):1143-53. PMID: 22035648.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  25. Hammerness PG, Surman CB, Chilton A. Adult attention-deficit/hyperactivity disorder treatment and cardiovascular implications. Curr Psychiatry Rep. 2011 Oct; 13(5):357-63. PMID: 21698412.
    Citations: 8     Fields:    Translation:Humans
  26. Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry. 2011 Oct; 50(10):978-90. PMID: 21961773.
    Citations: 20     Fields:    Translation:Humans
  27. Ulbricht C, Abrams TR, Basch E, Davies-Heerema T, Foppa I, Hammerness P, Rusie E, Tanguay-Colucci S, Taylor S, Ulbricht C, Varghese M, Weissner W, Woods J. An evidence-based systematic review of gymnema (Gymnema sylvestre R. Br.) by the Natural Standard Research Collaboration. J Diet Suppl. 2011 Sep; 8(3):311-30. PMID: 22432729.
    Citations: 1     Fields:    Translation:HumansAnimals
  28. Hammerness P, Biederman J, Petty C, Henin A, Moore CM. Brain biochemical effects of methylphenidate treatment using proton magnetic spectroscopy in youth with attention-deficit hyperactivity disorder: a controlled pilot study. CNS Neurosci Ther. 2012 Jan; 18(1):34-40. PMID: 21143432.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  29. Joshi G, Biederman J, Wozniak J, Doyle R, Hammerness P, Galdo M, Sullivan N, Williams C, Brethel K, Woodworth KY, Mick E. Response to second generation antipsychotics in youth with comorbid bipolar disorder and autism spectrum disorder. CNS Neurosci Ther. 2012 Jan; 18(1):28-33. PMID: 21114638.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  30. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Kotarski M, Spencer T. A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2010 Oct; 30(5):549-53. PMID: 20814332.
    Citations: 21     Fields:    Translation:HumansCellsCTClinical Trials
  31. Spencer TJ, Mick E, Surman CB, Hammerness P, Doyle R, Aleardi M, Kotarski M, Williams CG, Biederman J. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. J Atten Disord. 2011 May; 15(4):286-94. PMID: 20495161.
    Citations: 6     Fields:    Translation:Humans
  32. Wilens TE, Hammerness P, Martelon M, Brodziak K, Utzinger L, Wong P. A controlled trial of the methylphenidate transdermal system on before-school functioning in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2010 May; 71(5):548-56. PMID: 20492851.
    Citations: 8     Fields:    Translation:Humans
  33. Biederman J, Joshi G, Mick E, Doyle R, Georgiopoulos A, Hammerness P, Kotarski M, Williams C, Wozniak J. A prospective open-label trial of lamotrigine monotherapy in children and adolescents with bipolar disorder. CNS Neurosci Ther. 2010 Apr; 16(2):91-102. PMID: 20415838.
    Citations: 8     Fields:    Translation:Humans
  34. Joshi G, Wozniak J, Mick E, Doyle R, Hammerness P, Georgiopoulos A, Kotarski M, Aleardi M, Williams C, Walls S, Biederman J. A prospective open-label trial of extended-release carbamazepine monotherapy in children with bipolar disorder. J Child Adolesc Psychopharmacol. 2010 Feb; 20(1):7-14. PMID: 20166791.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  35. Surman C, Hammerness P, Petty C, Doyle R, Chu N, Gebhard N, Williams C, Biederman J. Atomoxetine in the treatment of adults with subthreshold and/or late onset attention-deficit hyperactivity disorder-not otherwise specified (ADHD-NOS): a prospective open-label 6-week study. CNS Neurosci Ther. 2010; 16(1):6-12. PMID: 20070786.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  36. Hammerness P, Georgiopoulos A, Doyle RL, Utzinger L, Schillinger M, Martelon M, Brodziak K, Biederman J, Wilens TE. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. J Child Adolesc Psychopharmacol. 2009 Oct; 19(5):493-9. PMID: 19877973.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  37. Wilens TE, Hammerness P, Utzinger L, Schillinger M, Georgiopoulous A, Doyle RL, Martelon M, Brodziak K. An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness. J Child Adolesc Psychopharmacol. 2009 Oct; 19(5):485-92. PMID: 19877972.
    Citations: 17     Fields:    Translation:HumansCTClinical Trials
  38. Hammerness P, Geller D, Petty C, Lamb A, Bristol E, Biederman J. Does ADHD moderate the manifestation of anxiety disorders in children? Eur Child Adolesc Psychiatry. 2010 Feb; 19(2):107-12. PMID: 19543790.
    Citations: 3     Fields:    Translation:Humans
  39. Hammerness P, Wilens T, Mick E, Spencer T, Doyle R, McCreary M, Becker J, Biederman J. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder. J Pediatr. 2009 Jul; 155(1):84-9, 89.e1. PMID: 19394037.
    Citations: 18     Fields:    Translation:HumansCTClinical Trials
  40. Hammerness P, Doyle R, Kotarski M, Georgiopoulos A, Joshi G, Zeitlin S, Biederman J. Atomoxetine in children with attention-deficit hyperactivity disorder with prior stimulant therapy: a prospective open-label study. Eur Child Adolesc Psychiatry. 2009 Aug; 18(8):493-8. PMID: 19377865.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  41. Hammerness P, McCarthy K, Mancuso E, Gendron C, Geller D. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review. Neuropsychiatr Dis Treat. 2009; 5:215-26. PMID: 19557116.
    Citations: 16     
  42. Ulbricht C, Weissner W, Basch E, Giese N, Hammerness P, Rusie-Seamon E, Varghese M, Woods J. Maitake mushroom (Grifola frondosa): systematic review by the natural standard research collaboration. J Soc Integr Oncol. 2009; 7(2):66-72. PMID: 19476741.
    Citations: 1     Fields:    Translation:HumansAnimals
  43. Ulbricht C, Weissner W, Hashmi S, Rae Abrams T, Dacey C, Giese N, Hammerness P, Hackman DA, Kim J, Nealon A, Voloshin R. Essiac: systematic review by the natural standard research collaboration. J Soc Integr Oncol. 2009; 7(2):73-80. PMID: 19476742.
    Citations: 3     Fields:    Translation:HumansAnimals
  44. Hammerness P, Surman C, Miller K. Update on adult attention-deficit/hyperactivity disorder. Curr Neurol Neurosci Rep. 2008 Nov; 8(6):484-9. PMID: 18957185.
    Citations: 3     Fields:    Translation:Humans
  45. Monuteaux MC, Faraone SV, Hammerness P, Wilens TE, Fraire M, Biederman J. The familial association between cigarette smoking and ADHD: a study of clinically referred girls with and without ADHD, and their families. Nicotine Tob Res. 2008 Oct; 10(10):1549-58. PMID: 18946774.
    Citations: 9     Fields:    Translation:Humans
  46. Hammerness PG, Wilens TE, Berul CI, Elkort MS. Supraventricular tachycardia in an adolescent with attention-deficit/hyperactivity disorder (ADHD). J Am Acad Child Adolesc Psychiatry. 2008 Feb; 47(2):219-220. PMID: 18216716.
    Citations: 1     Fields:    Translation:Humans
  47. Biederman J, Hammerness P, Doyle R, Joshi G, Aleardi M, Mick E. Risperidone treatment for ADHD in children and adolescents with bipolar disorder. Neuropsychiatr Dis Treat. 2008 Feb; 4(1):203-7. PMID: 18728799.
    Citations: 7     
  48. Biederman J, Makris N, Valera EM, Monuteaux MC, Goldstein JM, Buka S, Boriel DL, Bandyopadhyay S, Kennedy DN, Caviness VS, Bush G, Aleardi M, Hammerness P, Faraone SV, Seidman LJ. Towards further understanding of the co-morbidity between attention deficit hyperactivity disorder and bipolar disorder: a MRI study of brain volumes. Psychol Med. 2008 Jul; 38(7):1045-56. PMID: 17935640.
    Citations: 24     Fields:    Translation:Humans
  49. Biederman J, Mick EO, Surman C, Doyle R, Hammerness P, Michel E, Martin J, Spencer TJ. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. BMC Psychiatry. 2007 Sep 14; 7:49. PMID: 17868455.
    Citations: 10     Fields:    Translation:Humans
  50. Biederman J, Mick E, Spencer T, Doyle R, Joshi G, Hammerness P, Kotarski M, Aleardi M, Wozniak J. An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectr. 2007 Sep; 12(9):683-9. PMID: 17805214.
    Citations: 19     Fields:    Translation:Humans
  51. Harpold T, Biederman J, Gignac M, Hammerness P, Surman C, Potter A, Mick E. Is oppositional defiant disorder a meaningful diagnosis in adults? Results from a large sample of adults with ADHD. J Nerv Ment Dis. 2007 Jul; 195(7):601-5. PMID: 17632251.
    Citations: 8     Fields:    Translation:Humans
  52. Hammerness P, Harpold T, Petty C, Menard C, Zar-Kessler C, Biederman J. Characterizing non-OCD anxiety disorders in psychiatrically referred children and adolescents. J Affect Disord. 2008 Jan; 105(1-3):213-9. PMID: 17572506.
    Citations: 2     Fields:    Translation:Humans
  53. Ulbricht C, Armstrong J, Basch E, Basch S, Bent S, Dacey C, Dalton S, Foppa I, Giese N, Hammerness P, Kirkwood C, Sollars D, Tanguay-Colucci S, Weissner W. An evidence-based systematic review of Aloe vera by the natural standard research collaboration. J Herb Pharmacother. 2007; 7(3-4):279-323. PMID: 18928148.
    Citations: 5     Fields:    Translation:HumansAnimals
  54. Basch E, Bent S, Collins J, Dacey C, Hammerness P, Harrison M, Smith M, Szapary P, Ulbricht C, Vora M, Weissner W. Flax and flaxseed oil (Linum usitatissimum): a review by the Natural Standard Research Collaboration. J Soc Integr Oncol. 2007; 5(3):92-105. PMID: 17761128.
    Citations: 7     Fields:    Translation:HumansAnimals
  55. Ulbricht C, Basch E, Burke D, Cheung L, Ernst E, Giese N, Foppa I, Hammerness P, Hashmi S, Kuo G, Miranda M, Mukherjee S, Smith M, Sollars D, Tanguay-Colucci S, Vijayan N, Weissner W. Fenugreek (Trigonella foenum-graecum L. Leguminosae): an evidence-based systematic review by the natural standard research collaboration. J Herb Pharmacother. 2007; 7(3-4):143-77. PMID: 18928139.
    Citations: 7     Fields:    Translation:HumansAnimals
  56. Moore CM, Biederman J, Wozniak J, Mick E, Aleardi M, Wardrop M, Dougherty M, Harpold T, Hammerness P, Randall E, Lyoo IK, Renshaw PF. Mania, glutamate/glutamine and risperidone in pediatric bipolar disorder: a proton magnetic resonance spectroscopy study of the anterior cingulate cortex. J Affect Disord. 2007 Apr; 99(1-3):19-25. PMID: 17005256.
    Citations: 15     Fields:    Translation:Humans
  57. Biederman J, Mick E, Spencer T, Surman C, Hammerness P, Doyle R, Dougherty M, Aleardi M, Schweitzer K. An open-label trial of OROS methylphenidate in adults with late-onset ADHD. CNS Spectr. 2006 May; 11(5):390-6. PMID: 16641844.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  58. Wilens TE, Zusman RM, Hammerness PG, Podolski A, Whitley J, Spencer TJ, Gignac M, Biederman J. An open-label study of the tolerability of mixed amphetamine salts in adults with attention-deficit/hyperactivity disorder and treated primary essential hypertension. J Clin Psychiatry. 2006 May; 67(5):696-702. PMID: 16841618.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  59. Biederman J, Mick E, Faraone S, Hammerness P, Surman C, Harpold T, Dougherty M, Aleardi M, Spencer T. A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychopharmacol. 2006 Apr; 26(2):163-6. PMID: 16633145.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  60. Moore CM, Biederman J, Wozniak J, Mick E, Aleardi M, Wardrop M, Dougherty M, Harpold T, Hammerness P, Randall E, Renshaw PF. Differences in brain chemistry in children and adolescents with attention deficit hyperactivity disorder with and without comorbid bipolar disorder: a proton magnetic resonance spectroscopy study. Am J Psychiatry. 2006 Feb; 163(2):316-8. PMID: 16449488.
    Citations: 21     Fields:    Translation:Humans
  61. Hammerness PG, Vivas FM, Geller DA. Selective serotonin reuptake inhibitors in pediatric psychopharmacology: a review of the evidence. J Pediatr. 2006 Feb; 148(2):158-65. PMID: 16492422.
    Citations: 5     Fields:    Translation:Humans
  62. Ulbricht C, Basch E, Bent S, Boon H, Corrado M, Foppa I, Hashmi S, Hammerness P, Kingsbury E, Smith M, Szapary P, Vora M, Weissner W. Evidence-based systematic review of saw palmetto by the Natural Standard Research Collaboration. J Soc Integr Oncol. 2006; 4(4):170-86. PMID: 17022925.
    Citations: 6     Fields:    Translation:HumansAnimals
  63. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006 May 01; 59(9):829-35. PMID: 16373066.
    Citations: 62     Fields:    Translation:HumansCTClinical Trials
  64. Biederman J, Mick E, Hammerness P, Harpold T, Aleardi M, Dougherty M, Wozniak J. Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry. 2005 Oct 01; 58(7):589-94. PMID: 16239162.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  65. Ulbricht C, Basch E, Szapary P, Hammerness P, Axentsev S, Boon H, Kroll D, Garraway L, Vora M, Woods J. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complement Ther Med. 2005 Dec; 13(4):279-90. PMID: 16338199.
    Citations: 12     Fields:    Translation:HumansAnimals
  66. Ulbricht C, Basch E, Boon H, Ernst E, Hammerness P, Sollars D, Tsourounis C, Woods J, Bent S. Safety review of kava (Piper methysticum) by the Natural Standard Research Collaboration. Expert Opin Drug Saf. 2005 Jul; 4(4):779-94. PMID: 16011454.
    Citations: 5     Fields:    Translation:HumansAnimals
  67. Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S, Scott M, Podolski A, Ditterline JW, Morris MC, Moore H. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2005 Feb; 66(2):253-9. PMID: 15705013.
    Citations: 28     Fields:    Translation:HumansCTClinical Trials
  68. Hammerness P, Monuteaux MC, Faraone SV, Gallo L, Murphy H, Biederman J. Reexamining the familial association between asthma and ADHD in girls. J Atten Disord. 2005 Feb; 8(3):136-43. PMID: 16009662.
    Citations: 5     Fields:    Translation:Humans
  69. Basch E, Ulbricht C, Hammerness P, Bevins A, Sollars D. Thyme (Thymus vulgaris L.), thymol. J Herb Pharmacother. 2004; 4(1):49-67. PMID: 15273078.
    Citations: 9     Fields:    Translation:HumansAnimals
  70. Ulbricht C, Basch E, Hammerness P, Vora M, Wylie J, Woods J. An evidence-based systematic review of belladonna by the natural standard research collaboration. J Herb Pharmacother. 2004; 4(4):61-90. PMID: 15927926.
    Citations: 2     Fields:    Translation:HumansAnimals
  71. Wilens TE, Prince JB, Spencer T, Van Patten SL, Doyle R, Girard K, Hammerness P, Goldman S, Brown S, Biederman J. An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder. Biol Psychiatry. 2003 Jul 01; 54(1):9-16. PMID: 12842303.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  72. Hammerness P, Basch E, Ulbricht C, Barrette EP, Foppa I, Basch S, Bent S, Boon H, Ernst E. St John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics. 2003 Jul-Aug; 44(4):271-82. PMID: 12832592.
    Citations: 20     Fields:    Translation:HumansAnimals
  73. Basch E, Ulbricht C, Hammerness P, Vora M. Marshmallow (Althaea officinalis L.) monograph. J Herb Pharmacother. 2003; 3(3):71-81. PMID: 15277059.
    Citations: 1     Fields:    
  74. Ulbricht C, Basch E, Vora M, Sollars D, Rogers A, Basch S, Smith M, Moffet H, Hammerness P. Chaparral monograph:a clinical decision support tool. J Herb Pharmacother. 2003; 3(1):121-33. PMID: 15277076.
    Citations: 1     Fields:    
  75. Ulbricht C, Basch E, Ulbricht C, Sollars D, Hammerness P, Hashmi S. Wild yam (Dioscoreaceae). J Herb Pharmacother. 2003; 3(4):77-91. PMID: 15277124.
    Citations: 2     Fields:    
  76. Hammerness P, Parada H, Abrams A. Linezolid: MAOI activity and potential drug interactions. Psychosomatics. 2002 May-Jun; 43(3):248-9. PMID: 12075044.
    Citations: 3     Fields:    Translation:Humans
  77. Basch E, Ulbricht C, Hammerness P, Tsouronis C, Sollars D, Rogers A, Basch S, Bent S, Boon H, Ernst E. Kava monograph: a clinical decision support tool. J Herb Pharmacother. 2002; 2(4):65-91. PMID: 15277083.
    Citations: 2     Fields:    
  78. Hammerness P, Ulbricht C, Barrette EP, Boon H, Szapary P, Sollars D, Smith M, Tsourounis C, Bent S, Basch E. Shark cartilage monograph: a clinical decision support tool. J Herb Pharmacother. 2002; 2(2):71-93. PMID: 15277099.
    Citations: 1     Fields:    
  79. Nugent WC, Edney MT, Hammerness PG, Dain BJ, Maurer LH, Rigas JR. Non-small cell lung cancer at the extremes of age: impact on diagnosis and treatment. Ann Thorac Surg. 1997 Jan; 63(1):193-7. PMID: 8993264.
    Citations: 12     Fields:    Translation:Humans
  80. Pollack MH, Otto MW, Kaspi SP, Hammerness PG, Rosenbaum JF. Cognitive behavior therapy for treatment-refractory panic disorder. J Clin Psychiatry. 1994 May; 55(5):200-5. PMID: 8071270.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  81. Lafer B, Fava M, Hammerness P, Rosenbaum JF. The influence of DST and TRH test administration on depression assessments: a controlled study. Biol Psychiatry. 1993 Nov 01; 34(9):650-3. PMID: 8292694.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  82. Pollack MH, Hammerness P. Adjunctive yohimbine for treatment in refractory depression. Biol Psychiatry. 1993 Feb 01; 33(3):220-1. PMID: 8448273.
    Citations: 1     Fields:    Translation:Humans
  83. Pollack MH, Reiter S, Hammerness P. Genitourinary and sexual adverse effects of psychotropic medication. Int J Psychiatry Med. 1992; 22(4):305-27. PMID: 1363418.
    Citations: 12     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Hammerness's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (284)
Explore
_
Co-Authors (37)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.